These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25556716)

  • 1. Antitumor activity of an anti-CD98 antibody.
    Hayes GM; Chinn L; Cantor JM; Cairns B; Levashova Z; Tran H; Velilla T; Duey D; Lippincott J; Zachwieja J; Ginsberg MH; H van der Horst E
    Int J Cancer; 2015 Aug; 137(3):710-20. PubMed ID: 25556716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
    Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
    Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts.
    Lim K; Han SH; Han S; Lee JY; Choi HS; Choi D; Ryu CJ
    Cancer Immunol Immunother; 2024 Sep; 73(11):231. PubMed ID: 39261363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
    Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
    Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
    Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
    PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and preclinical characterization of a humanized antibody targeting CXCL12.
    Zhong C; Wang J; Li B; Xiang H; Ultsch M; Coons M; Wong T; Chiang NY; Clark S; Clark R; Quintana L; Gribling P; Suto E; Barck K; Corpuz R; Yao J; Takkar R; Lee WP; Damico-Beyer LA; Carano RD; Adams C; Kelley RF; Wang W; Ferrara N
    Clin Cancer Res; 2013 Aug; 19(16):4433-45. PubMed ID: 23812669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
    Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
    Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
    [No Abstract]   [Full Text] [Related]  

  • 11. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
    Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
    Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
    Sutherland MK; Yu C; Anderson M; Zeng W; van Rooijen N; Sievers EL; Grewal IS; Law CL
    MAbs; 2010; 2(4):440-8. PubMed ID: 20495353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
    Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
    Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
    Tóth G; Szöllősi J; Vereb G
    Cytometry A; 2017 Oct; 91(10):1021-1029. PubMed ID: 28945315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sym015: A Highly Efficacious Antibody Mixture against
    Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
    Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
    [No Abstract]   [Full Text] [Related]  

  • 19. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
    Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
    Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
    Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.